Immunic to Participate in Scientific and Investor Conferences in March
Provided By PR Newswire
Last update: Mar 3, 2025
NEW YORK, March 3, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in March:
Read more at prnewswire.com
